GSK says 'tailwinds' will lift its consumer healthcare business

Singapore

CHEAPER generic drugs, which are growing in double-digits, are invading the wellness segment of the global consumer healthcare business in a big way, giving giant drugmakers such as GlaxoSmithKline (GSK) a run for their money.

In Australia, GSK's household-name drug Panadol is facing competition from generic drugs, said Zubair Ahmed, head of consumer healthcare for Asia Pacific, the Middle East and Africa.